Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2025-04-25 Management Reports
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司2025年度提质增效重回报行动方案
Management Reports Classification · 95% confidence The document is a detailed action plan titled '2025 年度提质增效重回报行动方案' issued by 奥锐特药业股份有限公司. It outlines strategic initiatives for quality improvement, market expansion, R&D innovation, capacity optimization, shareholder return mechanisms including dividend and share repurchase plans, investor relations enhancement, governance system improvements, and risk warnings. The content is forward-looking and strategic rather than a financial report or regulatory filing. It does not contain financial statements or earnings data typical of Annual Reports (10-K), Interim Reports (IR), or Earnings Releases (ER). It also is not a simple announcement or certification but a comprehensive management plan document. This aligns best with a Management Reports (MDA) category, which covers management's detailed explanation of business trends, strategies, and outlook.
2025-04-25 Chinese
奥锐特药业股份有限公司2024年环境、社会和公司治理（ESG）报告（中文）
Environmental & Social Information Classification · 95% confidence The document is a comprehensive report from 奥锐特药业股份有限公司 for the year 2024, focusing on Environmental, Social, and Governance (ESG) aspects. It includes detailed sections on ESG governance, management frameworks, risk assessments, sustainability initiatives, corporate governance, internal controls, anti-corruption measures, information security management, and stakeholder engagement. The report references standards such as GRI Standards 2021, TCFD framework, UN SDGs, and Shanghai Stock Exchange guidelines for sustainability reporting. The content is extensive (15,000 characters), includes detailed narrative and data on ESG performance, governance structures, and social responsibility, and is explicitly titled as an ESG report for 2024. This matches the definition of Environmental & Social Information (Code: SR), which covers reports detailing the company's performance on Environmental, Social, and Governance factors. There is no indication that this is an announcement or a brief summary; it is the full report itself. Therefore, the correct classification is SR with high confidence.
2025-04-25 Chinese
奥锐特药业股份有限公司2024年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the auditor's opinion on the effectiveness of internal controls over financial reporting as of December 31, 2024. The content is a standalone audit report focusing on internal control effectiveness, not a full annual report or interim financial statement. The document length is 769 characters, which is short but contains the full audit opinion text, not just an announcement. Therefore, it fits the category of Audit Report / Information (AR). FY 2024
2025-04-25 Chinese
奥锐特药业股份有限公司2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including total assets, net profit, quarterly financial data, shareholder information, and business overview. It also mentions the audit report with an unqualified opinion by an accounting firm, which is typical for annual reports. The document length is 9340 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary notice. Therefore, this document is the actual Annual Report or a substantial summary of it, fitting the definition of an Annual Report (10-K). FY 2024
2025-04-25 Chinese
国泰海通证券股份有限公司关于奥锐特药业股份有限公司2024年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is a detailed onsite inspection report by a sponsor (Guotai Huatong Securities Co., Ltd.) regarding the continuous supervision work for Aoruite Pharmaceutical Co., Ltd. It covers governance, internal control, information disclosure, independence, use of raised funds, related party transactions, guarantees, major investments, and business operations during the supervision period. The report is dated for the year 2024 and includes findings and conclusions from the onsite inspection. It is not an annual report, earnings release, or a simple announcement. It is a standalone audit or inspection report related to regulatory compliance and continuous supervision, fitting the definition of an Audit Report / Information (AR). The document length is 2732 characters, which is sufficient for a substantive report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2024
2025-04-25 Chinese
奥锐特药业股份有限公司关于开展远期外汇交易业务的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the board of 奥锐特药业股份有限公司 regarding the company's decision to engage in forward foreign exchange trading business. It details the purpose, scope, risk analysis, and risk control measures related to this financial activity. The document is not a financial report, earnings release, or regulatory certification. It is an update on the company's capital management and risk hedging strategy involving foreign exchange derivatives. There is no indication that this is a full financial report or an announcement of voting results, management changes, or legal proceedings. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing and risk management activities involving foreign exchange transactions.
2025-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.